Mutational Signatures (v3.5 - November 2025)

DBS20 · GRCh37 · COSMIC v103

Mutational profile

Genome: GRCh37

Genome: GRCh38

Genome: mm9

Genome: mm10

Genome: rn6

Proportion of a particular doublet base substitution (DBS) mutation type among all DBS mutation types in the signature is represented by the height of each bar. There are 78 strand-agnostic DBS mutation types.

The reason there are 78 strand-agnostic DBS mutation types is as follows. First, there are 4 x 4 = 16 possible source doublet bases. Of these, AT, TA, CG, and GC are their own reverse complement. We can represent the remaining 12 as 6 possible strand-agnostic doublets (e.g. AC represents both AC and its reverse complement, GT). Thus, there are 4+6=10 source doublet bases. Because they are their own reverse complements, AT, TA, CG, and GC can each be substituted by only 6 doublets . For example, AT can be substituted by 3 doublets starting with C: CA, CC, CG. But AT can be substituted by only 2 doublets starting with G: GA and GC. This is because the mutation from AT>GG is already represented by its reverse complement, AT>CC. Similarly AT can be substituted by only 1 doublet starting with T: TA. This is because AT>TC is represented by its reverse complement, AT>GA, and AT>TG is represented by AT>CA. For the remaining doublets, which are not their own reverse-complements, there are 3 x 3 = 9 possible DBS mutation types. Thus, in total there are 4 x 6 + 6 x 9 = 78 strand-agnostic DBS mutation types (see enumeration in the accompanying Excel document).

Proposed aetiology

Aristolochic acid exposure.

Acceptance criteria

Supporting evidence for mutational signature validity

Validated evidence for real signature
Unclear evidence for real signature
Evidence for artefact signature
Background Identification study First included in COSMIC
Senkin et al. 2023 MedRxiv v3.4
Identification NGS technique Different variant callers Multiple sequencing centres
WGS Yes Yes
Technical validation Validated in orthogonal techniques Replicated in additional studies Extended context enrichment
Yes Yes -
Proposed aetiology Mutational process Support
Aristolochic acid exposure Experimental confirmation
Experimental validation Experimental study Species
Chen et al. 2024 Human cell lines

Summary of the technical and experimental evidence available in the scientific literature regarding the validation of the mutational signature.

Tissue distribution

Identified in clear cell renal cell carcinomas.

Associated signatures

DBS20 is associated with other aristolochic acid exposure signatures, SBS22a, SBS22b, and ID23.

Please note: While you do not need to log in to access this module, use of the data is still subject to the COSMIC Terms and Conditions which can be found here. By continuing on this site, you agree to these terms.